G-CSF to Treat Crohn's Disease

Exclusion Criteria

• •If any one of the above eligibility requirements is not met.
• •Use of any the following medications within the specified time period prior to the first dose of study drug or at any time during the study: Corticosteroid enema or 5-ASA enema or suppositories (7 days); Thalidomide (2 weeks); Corticosteroids (greater than 25 mg Prednisone/d or Prednisone equivalent) (4 weeks); Methotrexate, Cyclosporin, Tacrolimus (FK506, Prograf), Thalidomide, or Mycophenolate mofetil (CellCept) (4 weeks), or any biological therapy (cytokine, anti-cytokine, or integrin-based therapy); Monoclonal antibodies to TNF (4 months); any experimental agent (1 month); use of greater than 500 mg/d aspirin or any dose of other NSAID (24 hours).
• •Multiple bowel resections (greater than or equal to 200 cm) AND enteral or parenteral therapy to maintain weight.
• •Use of any other investigational agent within 30 days beginning the treatment phase of this study.
• •Any of the following abnormalities on an electrocardiogram: QT(c) greater than 0.48 sec, Mobitz type II second or third degree atrioventricular block, left bundle branch block or right bundle branch block with any fascicular block, changes consistent with acute ischemia.
• •A diagnosis of ulcerative colitis or indeterminate colitis;
• •Cushing's syndrome;
• •Coexisting Th2-type inflammatory diseases: a.) scleroderma b.) MODERATE persistent asthma defined as the presence of one of the features listed below:
• •Clinical features before treatment: daily symptoms, exacerbations that affect activity and sleep, nighttime asthma symptoms two to four times a week, peak expiratory flow (PEF) or forced expiratory volume (FEV1) greater than 60 percent to less than 80 percent of predicted, variability greater than 30 percent;
• •Daily medication required to maintain control:
• •Daily controller medication (especially for nighttime symptoms): inhaled corticosteroids and long acting bronchodilators
• •SEVERE persistent asthma defined as the presence of one of the features listed below:
• •Clinical features before treatment: continuous symptoms, frequent exacerbations, frequent nighttime asthma symptoms more than 4 times a week, daily physical activities limited by asthma symptoms, PEF or FEV1 less than 60 percent predicted, variability greater than 30 percent;
• •Daily medication required to maintain control:
• •Multiple daily controller medications (long-term);
• •high-dose inhaled corticosteroids or bronchodilators
• •oral corticosteroids
• •Current active bowel obstruction, intestinal perforation, significant GI hemorrhage, or known presence of high grade structure
• •HIV positivity or signs and symptoms consistent with HIV infection
• •Acute systemic or intestinal infection requiring antibiotics
• •Active hepatitis B or C
• •Decompensated liver disease (Childs-Pugh class B or C)
• •Hematocrit less than 30 percent; Platelet count less than 100,000 or greater than 700,000; PT INR greater than 1.3 or PTT prolonged by greater than 3 seconds; serum creatinine or BUN greater than 1.5 times the upper limit of normal (ULN); ALT(SGPT) or AST(SGOT) greater than 2 times the ULN; total bilirubin greater than 1.25 times the ULN; alkaline phosphatase greater than 1.5 times the ULN.
• •Pregnant or nursing women
• •History of cancer (other than resected cutaneous basal or squamous cell carcinoma; and in situ cervical cancer) with less than 5 years documentation of a disease-free state
• •History of myocardial infarction within the last 12 months
• •Patients expected to require surgery for their Crohn's disease within 12 weeks of study entry.
• •Any condition that, in the investigator's opinion, places the patient at undue risk by participating in the study.
• •History of anaphylactic reaction or hypersensitivity to G-CSF (Filgrastim) or proteins derived from E. coli
• •Presence of splenomegaly defined as a palpable spleen on physical exam.